Response to: ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ by Györfi et al
| Autor: | Jinoos Yazdany, Kimme L. Hyrich, Pedro Machado, Milena A. Gianfrancesco, Philip Robinson |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) Sarcoidosis Immunology General Biochemistry Genetics and Molecular Biology 03 medical and health sciences 0302 clinical medicine Rheumatology Recurrence Internal medicine medicine Humans Lupus Erythematosus Systemic Immunology and Allergy In patient Spondylitis Ankylosing Glucocorticoids Dexamethasone 030203 arthritis & rheumatology business.industry Arthritis Rheumatic disease COVID-19 medicine.disease Respiratory support 030104 developmental biology business Glucocorticoid medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2020-218328 |
| Popis: | We thank Gyorfi et al for their correspondence.1 The case they present demonstrates a potentially important point that was reported in our manuscript2: the effect of systemic glucocorticoids may worsen outcomes in patients with rheumatic disease. However, as has been highlighted recently by the results of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial, systemic glucocorticoids may have a role to play in treating COVID-19.3 Noteworthy, in the RECOVERY trial, dexamethasone (6 mg daily for 10 days) only reduced deaths in the patients that were ventilated (one-third reduction) or receiving oxygen (one-fifth reduction) but no benefit was seen among those patients who did not require respiratory support; moreover, the trial did not study … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|